Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Replimune Group stock | $29.01

Learn how to easily invest in Replimune Group stock.

Replimune Group Inc is a biotechnology business based in the US. Replimune Group shares (REPL) are listed on the NASDAQ and all prices are listed in US Dollars. Replimune Group employs 152 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Replimune Group

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – REPL – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Replimune Group stock price (NASDAQ: REPL)

Use our graph to track the performance of REPL stocks over time.

Replimune Group shares at a glance

Information last updated 2021-10-17.
Latest market close$29.01
52-week range$27.66 - $54.85
50-day moving average $31.42
200-day moving average $33.07
Wall St. target price$55.22
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-1.84

Buy Replimune Group shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
$20 per year
Financial advice powered by relationships, not commissions.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Replimune Group stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Replimune Group price performance over time

Historical closes compared with the close of $29.01 from 2021-10-22

1 week (2021-10-15) -3.78%
1 month (2021-09-24) -10.07%
3 months (2021-07-23) -12.06%
6 months (2021-04-23) -7.93%
1 year (2020-10-23) -35.82%
2 years (2019-10-23) 96.41%
3 years (2018-10-23) 144.60%
5 years (2016-10-20) N/A

Replimune Group financials

Gross profit TTM $0
Return on assets TTM -12.69%
Return on equity TTM -23.97%
Profit margin 0%
Book value $10.25
Market capitalisation $1.4 billion

TTM: trailing 12 months

Shorting Replimune Group shares

There are currently 2.1 million Replimune Group shares held short by investors – that's known as Replimune Group's "short interest". This figure is 1% up from 2.1 million last month.

There are a few different ways that this level of interest in shorting Replimune Group shares can be evaluated.

Replimune Group's "short interest ratio" (SIR)

Replimune Group's "short interest ratio" (SIR) is the quantity of Replimune Group shares currently shorted divided by the average quantity of Replimune Group shares traded daily (recently around 214646.02683179). Replimune Group's SIR currently stands at 9.69. In other words for every 100,000 Replimune Group shares traded daily on the market, roughly 9690 shares are currently held short.

However Replimune Group's short interest can also be evaluated against the total number of Replimune Group shares, or, against the total number of tradable Replimune Group shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Replimune Group's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Replimune Group shares in existence, roughly 40 shares are currently held short) or 0.0811% of the tradable shares (for every 100,000 tradable Replimune Group shares, roughly 81 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Replimune Group.

Find out more about how you can short Replimune Group stock.

Replimune Group share dividends

We're not expecting Replimune Group to pay a dividend over the next 12 months.

Replimune Group share price volatility

Over the last 12 months, Replimune Group's shares have ranged in value from as little as $27.66 up to $54.85. A popular way to gauge a stock's volatility is its "beta".

REPL.US volatility(beta: 2.46)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Replimune Group's is 2.4628. This would suggest that Replimune Group's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Replimune Group overview

Replimune Group, Inc. , a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

Frequently asked questions

What percentage of Replimune Group is owned by insiders or institutions?
Currently 8.884% of Replimune Group shares are held by insiders and 93.562% by institutions.
How many people work for Replimune Group?
Latest data suggests 152 work at Replimune Group.
When does the fiscal year end for Replimune Group?
Replimune Group's fiscal year ends in March.
Where is Replimune Group based?
Replimune Group's address is: 500 Unicorn Park Drive, Woburn, MA, United States, 01801
What is Replimune Group's ISIN number?
Replimune Group's international securities identification number is: US76029N1063
What is Replimune Group's CUSIP number?
Replimune Group's Committee on Uniform Securities Identification Procedures number is: 76029N106

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site